0 followers
Redesign Science develops and applies a molecular dynamics-driven platform for in silico drug discovery against emerging drug target classes. We work in partnership with Biotech and Pharma to co-develop novel small molecule therapeutics.
David Rooklin
Agilent Technologies
69 followers
Neuralink
62 followers
BioMarin Pharmaceutical
36 followers
GRAIL
27 followers
Avantor
10 followers
Cepheid
7 followers
Spectrix Analytical Services
1 follower
Editas Medicine
4 followers
Arcus Biosciences
3 followers
Merck
228 followers
Iovance Biotherapeutics
3 followers
Explore companies